Neoadjuvant atezolizumab plus chemotherapy in resectable non-small-cell lung cancer
Mené sur 30 patients atteints d’un cancer du poumon non à petites cellules résécable, cet essai de phase II évalue l’efficacité, du point de vue du taux de réponse pathologique majeure (tumeur résiduelle inférieure ou égale à 10% au moment du traitement chirurgical), et la toxicité d’un traitement néoadjuvant combinant atézolizumab, carboplatine et nab-paclitaxel
Immune checkpoint inhibitors in metastatic non-small-cell lung cancer are commonly used, either in patients with non-squamous disease, or in those with squamous disease but without ALK or EGFR mutations. 1 In the IMpower130 trial, 2 patients who received atezolizumab, a monoclonal antibody against PD-L1 (1200 mg administered intravenously every 3 weeks), plus carboplatin (area under the curve 6 mg/mL per min every 3 weeks) and nab-paclitaxel (100 mg/m 2 administered intravenously each week) for four or six 21-day cycles, had progression-free survival of 7·0 months, which was longer than that in patients who received chemotherapy alone (5·5 months; p<0·0001). Atezolizumab showed benefits regardless of PD-L1 expression
The Lancet Oncology , commentaire, 2019